nSMOL – Combining Nano Technology with LC-MS for Improved mAb Analysis

2 May 2018

Determining the efficacy and toxicity of biotherapeutics, such as mAbs, is fundamental to the development process. Whilst ELISA is a long-standing process used to determine drug concentration in blood samples, there are a number of caveats associated with its efficiancy and sensitivity that can be largely overcome with LCMS.  To streamline the process further, Shimadzu have developed an innovative nanotechnology-based bioanalysis kit, nSMOLTM, to eliminate sample preparation processes and increase the detection sensitivity further.